| Name | Title | Contact Details |
|---|
NeuBase is developing ultra precision genetic medicines targeting rare, monogenic diseases, therapeutic candidates for the treatment of myotonic dystrophy type 1 (DM1), Huntington`s disease (HD), and cancer-driving point mutations in KRAS G12V and G12D, which are involved in many tumor types and have historically been “undruggable.” for which there are no approved therapies, as well as more common genetic disorders, including cancers that are resistant to current therapeutic approaches. NeuBase`s pipeline includes
CORIA Laboratories, Ltd. is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
PBM consulting, provider nnetwork strategies, rebate benchmarking, global drug sourcing, client pricing, market assessments, MAC management, rebate aggregation.
Biomed International is a Burnaby, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.